Pharmaceutical composition comprising tricyclic compound for prevention or treatment of skin diseases
A technology of cyclic compounds and compositions, applied in skin diseases, drug combinations, metabolic diseases, etc., can solve problems such as no clear disclosure, and achieve the effect of treating or preventing rejection.
Inactive Publication Date: 2004-10-13
FUJISAWA PHARMA CO LTD
View PDF12 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
However, such dosage forms are not clearly disclosed
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0097] FK506 substance
[0098] Dissolve FK506 material with diethylene glycol monoethyl ether. Then 1,3-butanediol and propylene carbonate were added. After visual inspection of complete dissolution of the FK506 substance, carboxyvinyl polymer dispersed in a binary system of isopropyl myristate and diethyl sebacate was added in order to obtain the desired viscosity and a gel for external use. Glue preparation.
Embodiment 2
[0100] According to a method similar to Example 1, the following pharmaceutical compositions 2, 3, 4, 5 and 6 were prepared.
[0101] Composition number
Embodiment 3
[0103] Composition number
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
Provided is a pharmaceutical composition comprising a tricyclic compound (I) or its pharmaceutically acceptable salt; monohydric alcohol fatty acid esters; dibasic acid diesters; lower alkylene carbonates; butylene glycol; diethylene glycol mono(lower)alkyl ethers; and thickeners. It is satisfactory in stability and absorption kinetics and / or a low irritation potential.
Description
technical field [0001] The present invention relates to a pharmaceutical composition containing a tricyclic compound which is stable and has very satisfactory absorption kinetics and / or low irritation potential. The composition is useful in the treatment and prevention of various skin diseases. Background technique [0002] Said tricyclic compounds and pharmaceutically acceptable salts thereof used in the present invention are known to have excellent immunosuppressive activity, antimicrobial activity and other pharmacological activities, and thus have therapeutic or prophylactic Value in rejection, graft-versus-host disease, autoimmune diseases and infectious diseases [EP-A-0184162, EP-A-0323042 etc.]. [0003] In detail, the FK506 substance in the tricyclic compound (I) is shown to be useful in the treatment and prevention of transplant rejection in organ transplantation due to its very good immunosuppressive activity. [0004] It is mentioned in EP-A-0315978 that the eth...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(China)
IPC IPC(8): C07D498/18A61K31/436A61K31/4745A61K47/10A61K47/12A61K47/14A61K47/22A61K47/32A61K47/38A61P1/00A61P1/02A61P1/04A61P3/04A61P3/10A61P9/00A61P9/10A61P11/00A61P11/06A61P13/12A61P17/00A61P17/02A61P17/06A61P17/14A61P19/02A61P21/04A61P25/00A61P25/14A61P25/16A61P25/28A61P27/02A61P29/00A61P31/18A61P35/00A61P37/06
CPCA61K47/14A61K47/12A61K31/436A61K47/10A61K9/0014A61K31/4745A61K47/38A61K47/32A61P1/00A61P1/02A61P1/04A61P11/00A61P11/06A61P13/12A61P17/00A61P17/02A61P17/06A61P17/14A61P19/02A61P21/04A61P25/00A61P25/14A61P25/16A61P25/28A61P27/02A61P29/00A61P3/04A61P31/18A61P35/00A61P37/06A61P9/00A61P9/10A61P3/10C07D405/06
Inventor 上田聪坂井敏郎吉田惠里香
Owner FUJISAWA PHARMA CO LTD
PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.
